


FORM PTO 1449 (modified)				ATTY DOCKET NO. 50454-56101USCIP3		APPLICATION NO. 09/470,603	
 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)				APPLICANT Eugenio Cefali			
				FILING DATE 31 October 1997			GROUP 1615
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
CH	1	Expert Report of Cheryl D. Blume, Ph.D. (January 27, 2004) - Subject to Protective Order					
	2	Expert Report of Dr. Sergio Fazio (February 4, 2004) [Redacted Version] - Subject to Protective Order					
	3	Rebuttal Expert Report of Dr. Sergio Fazio (April 2, 2004) - Subject to Protective Order					
	4	Expert Report of Dr. Sergio Fazio Regarding U.S. Patent No. 6,676,967 (August 17, 2004) - Subject to Protective Order					
	5	Expert Report of Don W. Martens (February 6, 2004) [Redacted Version] - Subject to Protective Order					
	6	Expert Report of Don W. Martens Regarding U.S. Patent No. 6,676,967 (August 20, 2004) [Redacted Version] - Subject to Protective Order					
	7	Expert Report of Dr. Joseph R. Robinson (February 5, 2004) [Redacted Version] - Subject to Protective Order					
	8	Expert Report of Dr. Joseph R. Robinson Regarding U.S. Patent No. 6,676,967 (August 18, 2004) - Subject to Protective Order					
9	Rebuttal Expert Report of Thomas S. Foster, Pharm.D. (April 2, 2004) - Subject to Protective Order						

Casey Hagopian 5-31-2005

CH	10	Rebuttal Expert Report of Thomas S. Foster, Pharm.D. Regarding The '967 Patent (October 4, 2004) - Subject to Protective Order
	11	Rebuttal Expert Report of James W. McGinity, Ph.D. (April 2, 2004) - Subject to Protective Order
	12	Supplemental Rebuttal Expert Report of James W. McGinity, Ph.D. (August 18, 2004) - Subject to Protective Order
	13	Rebuttal Expert Report of James W. McGinity, Ph.D. Regarding The '967 Patent (September 30, 2004) - Subject to Protective Order
	14	Expert Report of Mark E. McGovern, M.D. (February 6, 2004) - Subject to Protective Order
	15	Expert Report of Mark E. McGovern, M.D. (August 20, 2004) - Subject to Protective Order
	16	Expert Report of Frank M. Sacks, M.D. (April 2, 2004) - Subject to Protective Order
	17	Expert Report of Frank M. Sacks, M.D. (August 20, 2004) - Subject to Protective Order
	18	Rebuttal Expert Report of Mary Ann Tucker, Esq. (April 2, 2004) - Subject to Protective Order
	19	Rebuttal Expert Report of Mary Ann Tucker, Esq. Regarding The '967 Patent (October 1, 2004) - Subject to Protective Order
	20	Carl J. Lavie, et al., <i>Marked Benefit with Sustained-Release Niacin Therapy in Patients with AIsolated@ Very Low Levels of High-Density Lipoprotein Cholesterol and Coronary Artery Disease</i> , Am. J. Cardiol. 1992;69:1083-1085
	21	Excerpts from the 1993, 2000, and 2002 editions of the Physician's Desk Reference
	22	<i>Niacin: Double-edged Sword for Lowering Cholesterol</i> , Tufts University Diet & Nutritional Letter (Tufts Univ., Boston, MA), August 1994, Vol. 12, issue 6
	23	Larsen, ML and Illingworth, DR, <i>Drug Treatment of Dyslipoproteinemia</i> , Med Clin N Am., 78:225-245 (1994)
✓	24	Lavie, Letter to Editor, JAMA 1994; 272:513-515

Casey Hagopian 5-31-2005

CH	25	Keenan, Letter to Editor, JAMA 1994; 272:513-515
	26	Shields & Beckmann, Letter to Editor, JAMA 1994; 272:513-515
	27	Thomas N. Tozer, Clinical Pharmacokinetics Concepts and Applications (3d ed. 1995) at Chapter 9, p. 120
	28	Excerpts from the United States Pharmacopela (1995)
	29	Morgan & Capuzzi Abstract, <i>Safe and Effective Treatment of Dyslipidemia by Niaspan, a New Sustained-Release Niacin</i> , Clinical Pharmacology & Therapeutics (February 1996)
	30	Morgan & Capuzzi Article, <i>Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients With Hypercholesterolemia: A Placebo-controlled Trial</i> , J. Cardiovasc. Pharmacol. Therapeut. 1(3):195-202 (July 1996)
	31	Capuzzi DM, et al., <i>Efficacy and Safety of An Extended-Release Niacin (Niaspan): A Long-Term Study</i> , Am J Cardiol. 1998;82:74U-81U
	32	Guyton JR, <i>Advances in Dyslipidemia: Discussion Session II</i> , Am J Cardiol, 1998: 82(12A): 85U-86U
	33	Knopp RH, et al., <i>Equivalent Efficacy of a Time-Release Form of Niacin (Niaspan) Given Once-a-Night Versus Plain Niacin in the Management of Hyperlipidemia</i> , Metabolism 47:1097-1104 (1998)
	34	American Diabetes Association: <i>Management of Dyslipidemia in Adults with Diabetes</i> , Diabetes Care 21:179-182, 1998
	35	Elam MB, et al., <i>Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease</i> , JAMA: 2000; 284:1263-1270
	36	Kesala R, et al., <i>Niacin (N) vs. Niaspan (NS) Treatment of the Atherogenic Lipid Profile (ALP; Small, Dense LDL, HDL2, HDLc and Triglycerides) and Lp(a) in Diabetic Patients (DP)</i> , Diabetes 49 (suppl. 1): A268 at 1114-P (June 2000)
	37	2001 NCEP Report at VI-11, Table VI.2-3
✓	38	Wang, W. et al., <i>Effect of Nicotinic Acid Administration on Hepatic Very Low Density Lipoprotein-Triglyceride Production</i> , Am J Physiol Endocrinol Metab., 280:E540-E547 (2001)

Casey Haggren 5-31-2005

CH	39	Smith SC, et al., <i>AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients with Atherosclerotic Cardiovascular Disease: 2001 Update</i> . AHA/ACC Scientific Statement, 1577-79
	40	Tavintharan S and Kashyap M, <i>The Benefits of Niacin in Atherosclerosis</i> , Curr Athero. Reports 2001; 3:74-82
	41	Meadows M., <i>Serious Liver Injury: Leading Reason for Drug Removals, Restrictions</i> , FDA Consumer Magazine, May-June 2001; http://www.fda.gov/fdac/features/2001/301_liver.html
	42	Grundy SM, et al., <i>Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated with Type 2 Diabetes</i> . Arch Intern Med. 2002; 162: 1568-1576
	43	American Diabetes Association: <i>Management of Dyslipidemia in Adults with Diabetes</i> , Diabetes Care 25:S74-S77, 2002
	44	Pan J, et al., <i>Niacin Treatment of the Atherogenic Lipid Profile and Lp(a) in Diabetes, Diabetes, Obesity and Metabolism</i> 4:255-261 (2002)
	45	Pan J, et al., <i>Extended-Release Niacin Treatment of the Atherogenic Lipid Profile and Lipoprotein(a) in Diabetes</i> , Metabolism 51:1120-1127 (2002)
	46	Meyers CD, et al., <i>Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia</i> , Ann Intern Med. 2003; 139:996-1002
	47	CDER <i>Guidance for Industry, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations</i> (March 2003)
	48	American Diabetes Association: <i>Dyslipidemia Management in Adults with Diabetes</i> , Diabetes Care 27:S68-S71, 2004
	49	Sample Kos Clinical Trial Medical Consent Form - Subject to Protective Order
✓	50	Sample Kos Clinical Trial Investigator's Statement - Subject to Protective Order
EXAMINER <i>Valery Haggopian</i>		DATE CONSIDERED <i>5-31-2005</i>